Amgen Forecast, price target & analysts
$439.26
1.79%
NYSE, Oct 23, 04:18 pm EDT.
Closed.
Index
Industry
Amgen Target price 2026 - Analyst rating & recommendation
Powered by
Amgen Classifications & Recommendation
Buy
47%
Hold
47%
Sell
7%
Amgen Price Target
| Target Price | $408.00 |
| Price | $439.26 |
| Deviation | 7.12% |
| Number of Estimates | 34 |
| 34 Analysts have issued a price target Amgen 2027 . The average Amgen target price is $408.00. This is 7.12% lower than the current stock price. The highest price target is $525.00 19.52% , the lowest is $227.25 48.27% . | |
| A rating was issued by 43 analysts: 20 Analysts recommend Amgen to buy, 20 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2027 of 7.12% . Most analysts recommend the Amgen stock at Buy or hold. |
Sales and Margin forecast 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
36 Analysts have issued a sales forecast Amgen 2026 . The average Amgen sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
37 Amgen Analysts have issued a net profit forecast 2026. The average Amgen net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
Current Amgen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 21 2026 |
| Guggenheim |
Neutral
➜
Neutral
|
Unchanged | Oct 13 2026 |
| Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 12 2026 |
| BMO Capital |
Market Perform
➜
Market Perform
|
Unchanged | Oct 12 2026 |
| UBS |
Buy
➜
Buy
|
Unchanged | Oct 09 2026 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 08 2026 |
| Cantor Fitzgerald |
Neutral
➜
Neutral
|
Unchanged | Oct 08 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Oct 21 2026 |
|
Unchanged
Guggenheim:
Neutral
➜
Neutral
|
Oct 13 2026 |
|
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Oct 12 2026 |
|
Unchanged
BMO Capital:
Market Perform
➜
Market Perform
|
Oct 12 2026 |
|
Unchanged
UBS:
Buy
➜
Buy
|
Oct 09 2026 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 08 2026 |
|
Unchanged
Cantor Fitzgerald:
Neutral
➜
Neutral
|
Oct 08 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
